LDLR and metabolic dysfunction-associated steatotic liver disease: Many rodent studies that focused on the rate-limiting enzyme 3-hydroxy-3-methylglutaryl-Coenzyme A reductase (HMGCR), the LDL receptor (LDLR), or sterol regulatory element binding protein, type 2 (SREBP-2) as the major cholesterol-related transcriptional regulator [5,22,23,24,25], did identify sex differences in disruption of cholesterol homeostasis and disease outcome (e.g., in NAFLD).